ArticleScientific reports2025
Sufentanil enhances the cortical neurogenesis of rats with traumatic brain injury via PI3K/AKT signal pathway.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aimed to explore the effects of Sufentanil on the cortical neurogenesis of rats with traumatic brain injury (TBI) and investigate the potential mechanisms. Rats with TBI model were prepared and divided into sham + vehicle, TBI + vehicle, TBI + Sufentanil and TBI + Sufentanil + LY294002 (PI3K/AKT signal pathway inhibitor) four groups. The oxidative stress, inflammation, nerve cell damage, melatonin, brain-derived neurotrophic factor (BDNF), neuron regeneration and p-AKT protein level in the cortex were detected with ELISA, TUNEL, qRT-PCR, immunofluorescence and Western blot. Pain behavioral test was assessed with mechanical withdrawal threshold (MWT). The results showed Sufentanil significantly decreased the oxidative stress and inflammation levels, increased melatonin and BDNF levels, protected the nerve cells from damage, enhanced the regeneration of immature or mature neurons and the p-AKT protein expression in the cortex, and boosted MWT in TBI rats. While the rats with TBI were treated with LY294002 and Sufentanil together, the abovementioned effects of Sufentanil on the TBI rats were partially reversed. Our results indicate Sufentanil enhances the cortical neurogenesis and inhibits mechanical allodynia of rats with TBI through suppressing the oxidative stress, inflammation response and increasing the melatonin and BDNF levels partly via PI3K/AKT signal pathway.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.